{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:40:30Z","timestamp":1761896430881},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,10,26]],"date-time":"2016-10-26T00:00:00Z","timestamp":1477440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,10,26]],"date-time":"2016-10-26T00:00:00Z","timestamp":1477440000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1038\/leu.2016.305","type":"journal-article","created":{"date-parts":[[2016,10,26]],"date-time":"2016-10-26T06:41:32Z","timestamp":1477464092000},"page":"517-519","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by 90Y-ibritumomab tiuxetan: 10-year follow-up of the phase 2 ECOG-ACRIN study E1499"],"prefix":"10.1038","volume":"31","author":[{"given":"M R","family":"Smith","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L I","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R D","family":"Gascoyne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E M","family":"Paietta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R H","family":"Advani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Forero-Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S J","family":"Horning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B S","family":"Kahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,10,26]]},"reference":[{"key":"BFleu2016305_CR1","unstructured":"Spurgeon SE, Till BG, Martin P, Goy AH, Dreyling MP, Gopal AK et al. Recommendations for clinical trial development in mantle cell lymphoma. J Natl Cancer Inst (in press)."},{"key":"BFleu2016305_CR2","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1200\/JCO.2002.20.5.1288","volume":"20","author":"OM Howard","year":"2002","unstructured":"Howard OM, Gribben JG, Neuberg DS, Grossbard M, Poor C, Janicek MJ et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol 2002; 20: 1288\u20131294.","journal-title":"J Clin Oncol"},{"key":"BFleu2016305_CR3","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Gr\u00fcnhagen U, Losem C et al. Study group indolent Lymphomas (StiL). Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013; 381: 1203\u20131210.","journal-title":"Lancet"},{"key":"BFleu2016305_CR4","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1056\/NEJMoa1412096","volume":"372","author":"T Robak","year":"2015","unstructured":"Robak T, Huang H, Jin J, Zhu J, Liu T, Samoilova O et al. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med 2015; 372: 944\u2013953.","journal-title":"N Engl J Med"},{"key":"BFleu2016305_CR5","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1056\/NEJMoa1200920","volume":"367","author":"HC Kluin-Nelemans","year":"2012","unstructured":"Kluin-Nelemans HC, Hoster E, Hermine O, Walewski J, Trneny M, Geisler CH et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med 2012; 367: 520\u2013531.","journal-title":"N Engl J Med"},{"key":"BFleu2016305_CR6","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1200\/JCO.2012.42.2444","volume":"30","author":"MR Smith","year":"2012","unstructured":"Smith MR, Li H, Gordon L, Gascoyne RD, Paietta E, Forero-Torres A et al. Phase II study of R-CHOP followed by 90Y-ibritumomab tiuxetan in untreated mantle cell lymphoma (MCL): 5 year follow-up of Eastern Cooperative Oncology Group E1499. J Clin Oncol 2012; 30: 3119\u20133126.","journal-title":"J Clin Oncol"},{"key":"BFleu2016305_CR7","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.beha.2012.04.004","volume":"25","author":"AP Skarbnik","year":"2012","unstructured":"Skarbnik AP, Smith MR . Radioimmunotherapy in mantle cell lymphoma. Best Pract Res Clin Haematol 2012; 25: 201\u2013210.","journal-title":"Best Pract Res Clin Haematol"},{"key":"BFleu2016305_CR8","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.3324\/haematol.2013.088377","volume":"98","author":"R Arranz","year":"2013","unstructured":"Arranz R, Garc\u00eda-Noblejas A, Grande C, Cannata-Ortiz J, S\u00e1nchez JJ, Garc\u00eda-Marco et al. First-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with 90Y-ibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase 2 pilot trial from the GELTAMO group. Haematologica 2013; 98: 1563\u20131570.","journal-title":"Haematologica"},{"key":"BFleu2016305_CR9","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMoa1306220","volume":"369","author":"ML Wang","year":"2013","unstructured":"Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013; 369: 507\u2013516.","journal-title":"N Engl J Med"},{"key":"BFleu2016305_CR10","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/bjh.13796","volume":"172","author":"D Chihara","year":"2016","unstructured":"Chihara D, Cheah CY, Westin JR, Fayad LE, Rodriguez MA, Hagemeister FB et al. Rituximab plus hyper-CVAD alternating with MTX\/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center. Br J Haematol 2016; 172: 80\u201388.","journal-title":"Br J Haematol"},{"key":"BFleu2016305_CR11","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/j.1365-2141.2011.08958.x","volume":"156","author":"F Merli","year":"2012","unstructured":"Merli F, Luminari S, Ilariucci F, Petrini M, Visco C, Ambrosetti A et al. Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi. Br J Haematol 2012; 156: 346\u2013353.","journal-title":"Br J Haematol"},{"key":"BFleu2016305_CR12","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1093\/annonc\/mdt070","volume":"24","author":"SH Bernstein","year":"2013","unstructured":"Bernstein SH, Epner E, Unger JM, Leblanc M, Cebula E, Burack R et al. A phase II multicenter trial of hyperCVAD MTX\/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213. Ann Oncol 2013; 24: 1587\u20131593.","journal-title":"Ann Oncol"},{"key":"BFleu2016305_CR13","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/j.1365-2141.2012.09174.x","volume":"158","author":"CH Geisler","year":"2012","unstructured":"Geisler CH, Kolstad A, Laurell A, Jerkeman M, R\u00e4ty R, Andersen NS et al. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC+autologous stem-cell support: still very long survival but late relapses do occur. Br J Haematol 2012; 158: 355\u2013362.","journal-title":"Br J Haematol"},{"key":"BFleu2016305_CR14","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1200\/JCO.2013.52.2466","volume":"32","author":"E Hoster","year":"2014","unstructured":"Hoster E, Klapper W, Hermine O, Kluin-Nelemans HC, Walewski J, van Hoof A et al. Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network. J Clin Oncol 2014; 32: 1338\u20131346.","journal-title":"J Clin Oncol"},{"key":"BFleu2016305_CR15","doi-asserted-by":"publisher","first-page":"6101","DOI":"10.1200\/JCO.2009.22.2554","volume":"27","author":"LE Damon","year":"2009","unstructured":"Damon LE, Johnson JL, Niedzwiecki D, Cheson BD, Hurd DD, Bartlett NL et al. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol 2009; 27: 6101\u20136108.","journal-title":"J Clin Oncol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2016305.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2016305","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2016305.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T16:22:27Z","timestamp":1648743747000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2016305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,26]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["BFleu2016305"],"URL":"https:\/\/doi.org\/10.1038\/leu.2016.305","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,26]]},"assertion":[{"value":"26 October 2016","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}